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Abstract
Background: To determine whether the number of optimally controlled hypertensive patients
is higher using self-measurement of blood pressure at home and ambulatory monitoring,
compared to using conventional blood pressure measurements at the doctor’s office.
Method: An observational, cross-sectional, multicentre, descriptive study of a random sample
of 237 primary health care patients, known to be hypertensive, from Badajoz (Spain). Blood
pressure was measured at the doctor’s office and by self-measurement at home. Those patients
showing good control by self-measurement were subjected to 24-hour ambulatory monitoring.
Optimal control was understood as blood pressure < 140/90 mm Hg when measured at the
doctor’s office, and < 135/85 mm Hg when self-measured at home and by daytime ambulatory
monitoring.
Results: Mean systolic/diastolic measurements at the doctor’s office and by self-measurement
were 145.6/83.9 and 134.0/78.7 mm Hg, respectively (p<0.000). In the population optimally
controlled by self-measurement and who subsequently received ambulatory monitoring, the
mean blood pressure was 121.8/73.4 and 125.6/76.2 mm Hg, respectively (p = 0.002; p < 0.000).
When measured at the doctor’s office blood pressure was controlled in about 29.5% (95% CI
23.7–35.3%) of patients, in 38% when self-measured (95% CI 31.4–44.2%; p < 0.000), and
in 24.5% when it was confirmed through ambulatory monitoring (95% CI 15.4–33.6%).
Sensitivity and positive predictive values of the office measurements for the detection of pa-
tients who were well-controlled by self-measurement were 50% and 64.3%, respectively, and
53.4% and 73.8% as regards ambulatory monitoring.
58
Cardiology Journal 2009, Vol. 16, No. 1
www.cardiologyjournal.org
Conclusions: A higher level of control is achieved with self-measurement at home not con-
firmed by ambulatory monitoring. Therefore, the white coat effect does not seem to influence
the percentage of well-controlled patients detected at the doctor’s office. Office blood pressure
does not appear to be useful in distinguishing which individual patients are optimally controlled.
(Cardiol J 2009; 16: 57–67)
Key words: hypertension, ambulatory blood pressure, home blood pressure,
blood pressure control, primary care
Introduction
Hypertension is the main risk factor for cardio-
vascular disease [1, 2], which is the primary cause
of death worldwide [3]. Blood pressure (BP) me-
asurement is a crucial aspect when it comes to
making clinical decisions, and precise and accurate
readings are needed. Even though all the epidemio-
logical and intervention studies are performed using
conventional blood pressure measurements
(CBPM) at the doctor’s office, this procedure is
fraught with many errors and biases affecting its
reproducibility and validity.
These CBPM limitations can be overcome by
using other techniques such as ambulatory blood
pressure monitoring (ABPM) and self blood pres-
sure measurement (SBPM) at home [4]. These
techniques use electronic devices, take more me-
asurements, and are performed outside the clinical
setting. The superiority of both techniques when
compared to CBPM has been demonstrated thro-
ugh their better correlation with organ damage and
their greater predictive capacity regarding the on-
set of diseases and cardiovascular mortality [5–8].
In population studies on the level of control
there was a high degree of patient unawareness of
hypertensive status, and poor level of control [9–12].
These results are slightly lower in Spain than in
neighbouring countries [13, 14]. Most primary he-
alth care (PHC) studies are not very representati-
ve of the hypertensive population (consecutive pa-
tients recruited at a doctor’s office), and different
methods are used to measure variables (measure-
ment techniques and values, timetables, instru-
ments, etc.). This makes them more difficult to
compare, but in Spain a significant trend towards
better control levels has been observed in recent
years [15, 16]. However, some authors believe that
findings from such studies could be affected by the
biases mentioned above as regards techniques, the
white coat effect (WCE), or morning BP increase.
These authors also consider that the percentage of
optimally controlled patients could be higher [17–
–19]. We do not know if there are any studies sho-
wing the control degree of BP in a representative
sample of a hypertensive population using SBPM
or ABPM to control these biases.
Many hypertensive patients have white coat
hypertension or WCE [20–23], and this could be
the main cause for the lack of accuracy of CBPM,
as well as the insufficient numbers of measure-
ments. It has been suggested that SBPM avoids
the WCE, but it does not have the necessary sen-
sitivity and positive predictive value (PPV) to be
used alone. Therefore, a confirmation of the effect,
by means of ABPM, is highly recommended [4, 20,
23–26].
Our aim is to determine if the bias control of
studies regarding control levels of BP, using me-
asurements outside the clinical setting, could pro-
vide better and more reliable control levels among
the hypertensive population. The protocol used for
measurements outside the clinic was proposed for
hypertension diagnosis and to start drug treatment
in patients with high BP in consecutive visits [4, 24].
We have used it to have a specific diagnosis of good
control outside the clinic, taking into account its
high specificity and good negative predictive value




descriptive study with a random sample of a hyper-
tensive population.
Target population
Population known to be hypertensive, aged
over 18 years, and treated at PHC clinics, from
three basic health zones in Badajoz, Spain. The
PHC service in this region covers a total of
87,953 inhabitants, including rural and urban po-
pulations.
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Sample
The sample size necessary to estimate a diffe-
rence of 36.5% versus 20% of controlled subjects
was calculated. The statistical power was 80%, and
the significance level was 95%.  The resulting sam-
ple size was 232 subjects. This amount was incre-
ased to 300 to cover any possible dropouts. The total
sample was divided into three sub-samples of
100 subjects for each of the three basic health zo-
nes. The cluster sampling technique was used and
was proportional to the number of hypertensive pa-
tients registered at each health care unit from eve-
ry health centre or local health facility. The indivi-
dual patients were selected by systematic random
sampling. The selected patients were phoned by their
respective doctors and asked to go to the PHC clinic.
Inclusion criteria:
— patients over 18 years old treated at the parti-
cipant PHC clinics;
— patients diagnosed with hypertesnion (JNC VII
criteria) [31], such diagnosis and/or the admi-
nistration of hypotensives being recorded in
their medical record;
— stable treatment for hypertension (pharmaco-
logical or non-pharmacological) administered
for at least 4 weeks before the start of study;
— having given informed consent to participate in
the study.
Exclusion criteria:
— patients unable or unwilling to give their consent;
— heart rate alterations (atrial fibrillation) preven-
ting BP from being measured by oscillometric
methods;
— cognitive impairment or physical disabilities
which, according to the family doctor and/or the
investigators, prevented the patient from lear-
ning and/or carrying out the SBPM and ABPM
techniques.
Study protocol
Data on family history of cardiovascular dise-
ases or hypertension, personal history of cardiova-
scular disease (ischemic heart disease, cerebrova-
scular disease, peripheral vascular disease, and
heart failure), smoking, diabetes (recorded in the
medical record, or treatment with anti-diabetic oral
drugs or insulin), alterations of glucose metabolism
(diagnosis of glucose intolerance or altered basal
glycemia recorded in medical record), hyperchole-
sterolemia (recorded in the medical record or be-
ing pharmacologically treated with antihyperlipide-
mic drugs), and hypertension evolution time, in
years, were recorded. Weight, height, abdominal
perimeter, and office BP were measured using stan-
dard guidelines [4] (3 consecutive BP measurements
were taken by the habitual doctor of every patient
using a mercury sphygmomanometer, with a 2-min
interval between them, recording the median va-
lue of the 2nd and 3rd measurements). The results of
the recent biochemical analysis (last 3 months) after
a 12-hour fasting period were noted. Such analysis
included glycemia, ions, total cholesterol, HDL,
LDL, and triglycerides. The presence of metabolic
syndrome was defined according to the criteria from
ATP III [27]; obesity by body mass index (BMI)
≥ 30; the white coat effect (WCE) as a poor control
by CBPM and a good control by SBPM or ABPM,
and a masked poor control with a good control by
CBPM and poor control by SBPM or ABPM. Col-
lection of all sample variables took place from Sep-
tember 2004 to November 2005.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
General study scheme (Fig. 1)
The participating patients were classified as
poorly controlled if they had a BP equal or superior
Figure 1. General scheme of the study; *no patients
were recruited over the duration of the study; **viola-
tion of study protocol; ***refused, could not be found,
or did not meet  ambulatory blood pressure measure-
ment (ABPM) quality criteria; CBPM — conventional
blood pressure measurement; SBPM — self blood pres-
sure measurement.
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to 140/90 mm Hg, and optimally controlled when the-
ir BP was lower, measured by CBPM. Subsequently,
patients were asked to perform home self-measu-
rements using an OMRON 705 CP monitor [28] by
their regular doctors: two measurements in the
morning and two at night, for three consecutive
working days. Prior to this they received oral and
written information on the ideal conditions for ta-
king this type of measurement [4], and use of the
monitor was demonstrated at the doctor’s office.
They were provided with a 12 cm × 26 cm cuff if
they had an arm circumference of less than 33 cm
and a 12 cm × 40 cm cuff, if their arm circumferen-
ce was larger. Measurements were printed out by
the monitoring device.
The self-measurements taken on the first day
were ignored because of the alarm reaction to using
the device [29], and the arithmetic mean of the other
8 measurements — corresponding to the 2nd and the
3rd day — were quantified. Patients whose mean BP
was higher than or equal to 135/85 mm Hg were clas-
sified as poorly controlled and were withdrawn from
the study. These patients were referred to their
doctor for appropriate hypertension management.
Patients with a mean BP less than 135/85 mm Hg
were classified as optimally controlled and were
invited to continue in the study using 24-hour
ABPM. This was performed using SpaceLabs 90207
monitors [30]. Good control was confirmed if they
had a mean daytime BP of lower than 135/85 mm Hg.
This criterion was established in order to avoid the
high variability of night measurements and the dif-
ferent activity-resting periods among the partici-
pants [4, 24].
Statistical analysis
The results of the survey, complementary te-
sts, and measurements were entered on an Access
database and the SPSS 13.0 statistics program was
applied. Quantitative variables were defined via the
means and standard deviation. Qualitative variables
were defined using percentages. BP means were
compared using the Wilcoxon test (when the CBPM
was included due to a non-normal distribution) and
using the t-test with the other paired data. When
dichotomous variables were compared to non-nor-
mal quantitative variables (number of antihyperten-
sive drugs), the Mann-Whitney U test was used, and
when such variables were normal, Student’s t-test
was used. Qualitative variables were assessed by
means of c². A crosstable was built in order to stu-
dy the sensitivity, specificity, predictive values, and
the odds ratio in the determination of the control
level by means of CBPM and SBPM and between
CBPM and ABPM. The level of concordance betwe-
en the different methods was studied using the
Kappa index.
Results
The study population characteristics are gi-
ven in Table 1. The high mean age, the large pro-
portion of women, and the high prevalence of
obese patients and metabolic syndrome in women
are noteworthy. Male patients received the high-
est mean number of drugs, and women the
highest proportion of non-pharmacological measu-
res, as single a treatment, with statistically signi-
ficant differences.
The mean systolic and diastolic BP obtained
using CBPM was 145.6 ± 15.9/83.9 ± 9.8 mm Hg
(Fig. 2). Using this technique, 29.5% of the patients
were controlled (95% confidence interval [CI]):
23.7–35.3%, with the level of control of the diastolic
component being higher than the systolic (Fig. 3).
There were no significant differences in the level
of control as regards gender, age, BMI, metabolic
syndrome, or number of drugs the patients were
receiving (Table 2, 3).
Using SBPM, the systolic and diastolic BP
were 140.0 ± 19.1/78.7 ± 9.9 mm Hg, which are
significantly lower than those obtained using CBPM
(Fig. 2). The means of the values obtained in the
different days are given in Figure 4. The measure-
ments obtained during the first day were not taken
into account for the calculations of systolic and dia-
stolic BP means, according to the general study
scheme. The mean systolic BP decreased each day,
and statistically significant differences among the
means of the three days were found. The mean dia-
stolic BP also decreased, and statistically significant
differences were found between the first day and
days 2 and 3. No differences were found between
the last two days. Mean systolic BP from 2° and 3°
day by the morning was 142.0 mm Hg (20.6; 139.4–
–144.7) and systolic BP in the evening was 137.9
(19.4; 135.4–140.4; p = 0.000). Diastolic BP
by the morning was 79.9 mm Hg (10.4; 78.5–81.2)
and in the evening 77.6 mm Hg (10.4; 76.2–78.9;
p = 0.000). Control degree with SBPM obtained by
the morning was 34.2% and in the evening 43.9%
(p = 0.000) with a Kappa index of 0.587 (SE 0.005;
p = 0.000).
About 38% of hypertensive patients were well-
controlled using SBPM (95% CI 31.8–44.2%),
28.6% more than with CBPM (p < 0.000), with the
level of control of the diastolic component being
greater than that of the systolic component (Fig. 3).
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The population who were poorly controlled using
this method had a higher mean age and received,
on average, a greater number of antihypertensive
drugs (Table 3).
When SBPM was used, the prevalence of the
white coat effect was 19%, and that of masked poor
control was 10.5% (Table 4).
The optimally controlled BP using SBPM was
confirmed by ABPM in 68.2% of the patients, with
control of the diastolic component being better (as
in the previous cases; Fig. 3), i.e. 24.5% (95% CI
15.4–33.6%) of the hypertensive patients from the
initial sample. Systolic and diastolic BP means ob-
tained were higher than the means obtained using
SBPM (Table 5). No significant differences were
observed between the two samples regarding gen-
der, age, BMI, presence of metabolic syndrome, or
mean quantity of drugs (Table 2, 3).
Pharmacological treatment with antihyperten-
sive drugs showed its influence only in the control
degree detected by SBPM, good control in 51.1%
of patients with no pharmacological drugs and 34.9%
of good control in drugs treated patients (p = 0.044).
There were no differences with CBPM 28.9% vs.
29.7% (p = 0.916) and by ABPM 65% vs. 69.2%
(p = 0.722), respectively.
CBPM sensitivity for the detection of well-con-
trolled patients was about 50%, compared to SBPM,
and had a PPV of 64.3%. Both the negative predic-
tive value (NPV) and the specificity were higher
(Table 4). These parameters are presented in
Table 6, which compares the CBPM results with
ABPM results. Figure 5 shows the proportion of
every patient in each situation when using different
techniques.
Discussion
It is essential to have valid, periodical estima-
tes on the level of control of risk factors for the pri-
mary cause of death in order to assess the inter-
mediate results of work being performed in the field
of PHC cardiovascular prevention. In the case of
hypertension, it is becoming increasingly evident
that BP measurement methods carried out outside
the clinical setting, despite being considered com-
plementary to the measurements taken there [4, 31],
are superior in stratifying risk [32–34], and recom-
mendations for their use are becoming more wide-
spread [35]. Studies to determine the level of con-
trol of the population treated at PHC clinics using
these techniques [19] are scarce, and they have
Table 1. Study population characteristics.
Total Male Female Sig. level
(n = 237) (n = 92; 38.8%) (n = 145; 61.2%)  (p)
Mean age (years) 65.2 ± 10.5 63.7 ± 11.4 66.4 ± 9.8 0.020
95% confidence interval 63.9–66.6  61.2–66.1 64.8–68.0
Hypertension mean time (years) 9.1 ± 6.8 7.5 ± 5.2 10.2 ± 7.5 0.001
95% confidence interval 8.2–10.0 6.4–8.6 9.0–11.5
Active smoking (%) 13.9 20.9 9.7 0.016
Diabetes (%) 19.4 18.5 20 0.773
Other hydrocarbon 14.3 12 15.9 0.403
alterations (IFG, IGT) (%)
Mean body mass index (BMI) 30.6 ± 4.6 30.0 ± 3,4 30.9 ± 5.1 0.112
95% confidence interval 30.01–31.19 29.3–30.7 30.1–31.8
Obesity (%) (BMI ≥ 30) 48.7 47.3 49.7 0.721
Mean cholesterol [mg/dL] 207.1 ± 34 202.6 ± 35.5 209.6 ± 31.9 0.053
95% confidence interval 202.8–211.5 195.1–210.1 204.3–215.0
Metabolic syndrome (%) 43.2 29.7 51.7 0.001
Associated cardiovascular disease (%) 17.3 20.7 15.2 0.277
Number of antihypertensive drugs (%)
0 only LSM 19 12 23.4 0.028
1 51.9 51.1 52.4
2 23.2 27.2 20.7 0.032
3 or more 5.9 9.8 3.5
IFG — impaired fasting glycemia: basal glycemia in venous blood ranging from 110 to 125 mg/dL, both included; IGT — impaired glucose tolerance:
oral glucose test tolerance after 2 h between 140 and 199 mg/dL, both included; LSM — life style modifications; p — sig. level t test or c²
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several biases, including selection biases (such as
using consecutive patients) or information biases
(use of SBPM for only one day or failure to take into
account the sensitivity, specificity, and predictive
value limitations of these techniques).
With CBPM, we obtained a lower level of BP
control than that published in Spain by other authors
[15, 16]. This finding could be due to the random
selection of the sample, including patients who
would not usually visit the doctor (probably with
a lower level of control) and who are, therefore, less
likely to be recruited for studies in consecutive
patients. Using SBPM, the level of control incre-
ases to almost 40%, an increase of 28.6% over the
well-controlled population by means of CBPM. This
good control with SBPM is confirmed by ABPM in
only a little over two thirds of patients, which me-
ans that the real level of control could decrease to
24.5%, even less than that obtained by CBPM, thus
questioning the validity of SBPM.
Although in most studies the correlation be-
tween SBPM and ABPM is good, some differences
are bound to exist due to the characteristics of each
technique [37]: patients at rest in ideal conditions
with SBPM versus patients performing everyday
activities with no posture restrictions or mental or
physical exercise restrictions, with ABPM. This
explains the differences we found between the two
methods as regards the mean values for systolic and
diastolic BP (higher values were obtained with ABPM)
and agrees with other studies, both population-
Figure 2. Blood pressure components (mean, SD, CI) by
conventional blood pressure measurement (CBPM) and
self blood pressure measurement (SBPM); SBP — systo-
lic blood pressure; DBP — diastolic blood pressure; SBP
and DBP by CBPM presented a non-normal distribution.
Figure 3. Control level of blood pressure according to systolic and diastolic components, and both, with all the
different measurements techniques; *only those patients presenting a good control by means of self blood pressure
measurement (SBPM) received ambulatory blood pressure measurement (ABPM); SBP — systolic blood pressure;
DBP — diastolic blood pressure; CBPM — conventional blood pressure measurement.
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-based [38] and those in untreated hypertensive pa-
tients [39].
The low rate of confirmation of the optimal
control patients by ABPM corresponds with the
previously demonstrated deficient PPV of the
SBPM for the detection of the WCE and which the
protocol relies on. Several studies find similar iso-
lated clinical hypertension prevalence with both me-
thods, but the mismatch among the identified indi-
viduals reaches 20–25% [37].
One of our most noteworthy findings was the
low sensitivity in the detection of optimal control
among the hypertensive patients by means of
CBPM compared to SBPM. PPV is also low, tho-
ugh to a lesser extent. Doctors should think twice
before giving an optimal control diagnosis, and the
results should be confirmed using another techni-
que, in spite of this parameter being dependent on
the prevalence of the studied problem.
On the other hand, we obtained acceptable spe-
cificity and NPV. Therefore, doctors may give
a confident no-control diagnosis, which is contrary
to the reasoning commonly used in clinical practice.
Furthermore, the CBPM method offers likelihood
ratios — both positive and negative — that are in-
sufficient for use as a diagnostic method in deter-
mining which patients are well controlled in com-
parison to SBPM, which is confirmed by the low
Kappa index between them. This interpretation of
Table 2. Characteristics of the population regarding the level of control (qualitative variables) (c² test).
Sex Diabetes Metabolic syndrome
M F p Yes No p Yes No p
CBPM % control* 33.7 26.9 0.267 32.6 28.8 0.611 28.4 30.6 0.718
SBPM % control** 35.9 39.3 0.595 32.6 39.3 0.404 35.3 40.3 0.433
ABPMd % control** 73.6 59.4 0.173 73.3 67.1 0.640 75.0 64.2 0.298
M — male; F — female; *blood pressure control if < 140/90 mm Hg; **blood pressure control if < 135/85 mm Hg; CBPM — conventional blood
pressure measurement; SBPM — self blood pressure measurement; ABPMd — ambulatory blood pressure monitoring daytime
Table 3. Characteristics of the population regarding the level of control (quantitative variables).
Average age (years) Mean BMI Average no. drugs
OC PC p† OC PC p† OC PC p#
CBPM* 64.47 65.57 0.468 30.34 30.71 0.568 1.14 1.17 0.812
SBPM** 62.23 67.09 0.001 30.37 30.74 0.540 1.02 1.25 0.032
ABPMd** 62.88 59.67 0.173 30.65 29.25 0.224 1.03 1.11 0.625
*blood pressure control if < 140/90 mm Hg; **blood pressure control if < 135/85 mm Hg; †Student’s t-test; #Mann-Whitney U test; OC — optimally
controlled; PC — poorly controlled; BMI — body mass index; CBPM — conventional blood pressure measurement; SBPM — self blood pressure
measurement; ABPMd — ambulatory blood pressure monitoring daytime
Figure 4. Analysis of the measurements obtained by
means of self blood pressure measurement (SBPM) re-
garding different days (T-test for paired samples); SBP
— mean systolic blood pressure of the 4 measurements
taken per day; DBP — mean diastolic blood pressure of
the 4 measurements taken per day.
64
Cardiology Journal 2009, Vol. 16, No. 1
www.cardiologyjournal.org
the findings agrees with the ABPM results, where
the proportion of well-controlled patients by this
method and those who were controlled or not
by means of the CBPM (36.5%/31.8%) is similar
(Table 6).
In view of our results, we can also question the
use of SBPM for the diagnosis and control of hy-
pertensive patients. There are new investigations
that question this point too [40, 41]. Until further
studies are performed that demonstrate which tech-
niques are more effective in reducing the risk of
treatment decisions, this question will remain unso-
lved. However, the prognostic results obtained in
the PAMELA study [42] give added value to the
information obtained with SBPM for improving the
predictive value for cardiovascular events and de-
ath from all causes. This fact, together with the
greater accessibility, suggests that its use may be
recommended as long as its limitations are taken
into account. We must also emphasize the impro-
ved prognostic value of measurements obtained by
CBPM when compared to other techniques. There-
fore, for the time being, the most reasonable way for-
ward would be to integrate all the information using
protocols that, like those we used, try to improve the
decision making process in clinical practice.
Limitations of the study
There may have been a selection bias because
we excluded patients who were immobilized or who
had cognitive or physical deficiencies and therefore
could not perform the self-measurement and ambu-
latory techniques. Such a bias might have decreased
the proportion of patients suffering advanced hyper-
tensive disease. In spite of this there were some
patients (17.3%) with established cardiovascular
Table 6. Crosstabs level control through conventional blood pressure measurement (CBPM) and
ambulatory blood pressure monitoring in the daytime (ABPMd).
OC ABPMd PC ABPMd Total
OC CBPM 31 (36.5%) 11 (13%) 42 (49.4%) PPV: 73.8%
PC CBPM 27 (31.8%) 16 (18.9%) 43 (50.6%) NPV: 37.2%
Total 58 (68.2%) 27 (31.8%) 85 (100%)
Sensitivity: 53.4% Specificity: 59.3%
OC CBPM — optimal control (< 140/90 mm Hg); PC CBPM — optimal control (≥ 140/90 mm Hg); OC SBPM — optimal control (< 135/85 mm Hg);
BC ABPMd — poor control (≥ 135/85 mm Hg); PPV — positive predictive value; NPV — negative predictive value; likelihood ratio (positive) — 1.31;
likelihood ratio (negative) — 0.79; Kappa index — 0.11 (p = 0.275)
Table 4. Crosstabs level control through conventional blood pressure measurement (CBPM) and self
blood pressure measurement (SMBP).
OC SBPM PC SBPM Total
OC CBPM 45 (19%) 25 (10.5%) 70 (29.5%) PPV: 64.3%
PC CBPM 45 (19%) 122 (51.5%) 167 (70.5%) NPV: 73.1%
Total 90 (38%) 147 (62%) 237 (100%)
Sensitivity: 50% Specificity: 83%
OC CBPM — optimal control (< 140/90 mm Hg); PC CBPM — poor control (≥ 140/90 mm Hg); OC SBPM — optimal control (< 135/85 mm Hg);
PC SBPM — poor control (≥ 135/85 mm Hg; PPV — positive predictive value, VPN — negative predictive value; likelihood ratio (positive) — S/1-E: 2.94;
likelihood ratio (negative) — 1-S/E: 0.60; Kappa index of agreement — value 0.345 (p < 0.000)
Table 5. Systolic and diastolic means of optimally controlled population through self blood pressure
measurement (SBPM) compared to ambulatory blood pressure monitoring in the daytime (ABPMd).
SBPM* (n = 90) ABPMd (n = 85) p (t-test paired samples)
Systolic mean [mm Hg] 121.8±8.7 125.6±11.8 < 0.002
95% confidence interval 120.0–123.7 123.0–128.2
Diastolic mean [mm Hg] 73.4±7.1 76.2±8.8 < 0.000
95% confidence interval 71.9–75.0 74.3–78.1
*Well-controlled population by means of SBPM < 135/85 mm Hg
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Figure 5. Control level when using different techniques; PC — poor control; OC — optimal control; (%) up —
percentage from portion; (%) down — percentage from total; conventional blood pressure measurement (CBPM):
OC: PA < 140/90 mm Hg; self blood pressure measurement (SBPM): OC: PA < 135/85 mm Hg; ambulatory blood
pressure monitoring daytime (ABPMd): OC: PA < 135/85 mm Hg.
disease. Likewise, we must take into account the
21% of patients who were lost after the initial sam-
ple calculations. The lack of response, however, was
mainly due to not having the collaboration of some
family physicians.
With regard to SBPM, it may have been neces-
sary to include another measurement day, or incre-
ase the number of measurements per day, because
the systolic arterial pressure means were not sta-
ble between the second and the third day. Never-
theless, the trend was to keep decreasing, and the
result of the bias would probably have been to ob-
tain a smaller total mean regarding all the days. One
factor that was also taken into account was the fact
that the patients could change the results obtained
by SBPM and provide the doctor with their prefer-
red results [43]. Even though we used monitors
with memory storage and printers, this eventuali-
ty was not studied.
Finally, some of our results could have been
different if we had performed ABPM on all the pa-
tients. There are patients that may have bad con-
trol by SBPM and good control by ambulatory blo-
od pressure. This matter was not investigated in our
study because of its design based on the high spe-
cificity and negative predictive value of SBPM com-
pared with ABPM in WCE detection [23, 39], and of
course the lower disposal of this technique in Pri-
mary Healthcare Centres. In others words, SBPM
has a high sensitivity and positive predictive value
to detect bad control patients, but lower to detect
those who are well controlled. If we extrapolate the
results of other investigators regarding patients that
have bad control by self-monitoring and optimal by
ABPM [23, 39], with regard to our study, the con-
trol degree out of the office could be improved by
between 2.4% and 11%.
Restrictive criteria of optimal control outside
the clinic (SBPM and ABPM) could influence the
results in this setting.
Conclusions
In summary, we may conclude that the level of
control in the hypertensive population does not im-
prove using measurement techniques outside the
clinical setting. Office blood pressure measurements
do not seem to be useful in distinguishing which
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individual patients are poorly- or well-controlled, and
are more valid when they show no control.
The use of measurement with ambulatory de-
vices may always be advisable, but especially when
the results show good control in the office.
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